{
    "clinical_study": {
        "@rank": "45369", 
        "arm_group": {
            "arm_group_label": "Metformin", 
            "arm_group_type": "Experimental", 
            "description": "Metformin 500 mg. extended release (taken orally)  one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months."
        }, 
        "brief_summary": {
            "textblock": "The investigator's global hypothesis is that women with Polycystic Ovary Syndrome (PCOS) can\n      be separated into subtypes based on their response to metformin.  The investigators propose\n      here to use both targeted and non-targeted metabolomic approach to identify pathways\n      associated with metformin's effect on insulin sensitivity and endothelial function. This\n      pilot project will be the foundation for developing tailored therapeutic approaches to\n      Polycystic Ovary Syndrome and identifying novel drug targets."
        }, 
        "brief_title": "Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Polycystic Ovary Syndrome", 
        "condition_browse": {
            "mesh_term": "Polycystic Ovary Syndrome"
        }, 
        "detailed_description": {
            "textblock": "The investigators propose to use both targeted and non-targeted metabolomic approaches to\n      identify pathways associated with metformin's effect on insulin sensitivity, weight,\n      androgens and endothelial function.  This project will be the foundation for developing\n      tailored therapeutic approaches to Polycystic Ovary Syndrome and identifying novel drug\n      targets.  This pilot project is intended to inform the development of hypothesis and\n      specific aims for a future grant application to National Institutes of Health (NIH)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion:\n\n          -  Body mass index (BMI) greater than or equal to 25\n\n          -  Polycystic Ovary Syndrome criteria of both oligomenorrhea (<9 menses per year) and\n             androgen excess [clinical hirsutism (Ferriman-Gallway score >8 or severe acne) or\n             elevated testosterone].\n\n          -  Taking no medications for the treatment of insulin resistance.\n\n        Exclusion:\n\n          -  Diagnosis of Cushing's syndrome\n\n          -  Untreated hypo/hyperthyroidism\n\n          -  Elevated prolactin\n\n          -  Congenital adrenal hyperplasia\n\n          -  Renal insufficiency (creatinine > 1.5)\n\n          -  Diabetes\n\n          -  Medications that can significantly affect endothelial function\n\n          -  Pregnancy\n\n          -  Breast Feeding\n\n          -  Taking oral contraceptives\n\n          -  Currently smoking"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02086526", 
            "org_study_id": "13-000692"
        }, 
        "intervention": {
            "arm_group_label": "Metformin", 
            "description": "Approximately 37 patients will start metformin therapy 3 months after their visit 2.  All other patients will receive metformin therapy at their visit 2.", 
            "intervention_name": "Metformin", 
            "intervention_type": "Drug", 
            "other_name": "Glucophage, Glucophage XR, Glumetza, Fortamet, Riomet"
        }, 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "contact": {
                "email": "johnson.tammi@mayo.edu", 
                "last_name": "Tammi R Johnson", 
                "phone": "507-255-6940"
            }, 
            "contact_backup": {
                "email": "giesler.paula@mayo.edu", 
                "last_name": "Paula Giesler", 
                "phone": "507-255-8345"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }, 
            "investigator": [
                {
                    "last_name": "Alice Y Chang, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Asma Javed, MBBS", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Targeting Pathophysiologic Pathways in Polycystic Ovary Syndrome Using a Response to Metformin Phenotype", 
        "other_outcome": [
            {
                "measure": "Change in Weight", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, 3 months"
            }, 
            {
                "measure": "Change in Testosterone", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, 3 months"
            }
        ], 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Alice Chang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Insulin sensitivity will be calculated using an oral glucose minimal model.  Insulin under the curve will be calculated geometrically with a the trapezoidal rule.", 
            "measure": "Change in Insulin Sensitivity (SI) after 3 Months of Metformin Therapy", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline, 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02086526"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Alice Y Chang", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The ratio of Peripheral Digital Arterial Tonometry (PAT) signal after cuff release compared with baseline is calculated through a computer algorithm normalizing for baseline measurements and indexing to measurements in the contra-lateral arm.  The calculated ratio reflects the reactive hyperemia index (RHI).", 
            "measure": "Change in Peripheral Flow-Mediated Vasodilatation after 3 Months of Metformin Therapy", 
            "safety_issue": "Yes", 
            "time_frame": "baseline, 3 months"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}